Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
AC Immune of Switzerland will work with Janssen on a therapeutic Tau-targeted vaccine for Alzheimer’s that is in Phase Ib and which could be used in combination with beta-amyloid based approaches to maximize therapeutic responses to the disease. J&J also has licensed a pioneering microbiome drug from Vedanta.
You may also be interested in...
TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study
While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.
Private Neurology Companies: Back In The Saddle Again
START-UP reviews five years of fundraising and exit activities for privately held biopharma companies developing neurology treatments. Next month we’ll delve into neurology medtech and diagnostics companies’ capital-raising and bow-outs.
A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.